European Pharmaceutical Review

JULY 21, 2023

The company intends to invest approximately $90 million at its site in Ljubljana, Slovenia, to establish a dedicated Sandoz Biopharma Development Center by 2026. They drive competition and cost savings, helping to address the rising financial pressures faced by global healthcare systems.

Biopharma 98

Biopharma Manufacturing Competition Healthcare 98

Clarivate

APRIL 24, 2023

healthcare payers and providers are consolidating at a dizzying clip as they seek to gain market share, increase access to care and secure clinical control to improve health outcomes. CVS’ bid for Oak Street is in keeping with nearly two decades of evolution toward becoming an integrated payer and provider.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

MedCity News

JANUARY 11, 2024

Generic competition has eroded sales of multiple sclerosis drug Ampyra, marketed as Fampyra outside the U.S. Biogen told Acorda Therapeutics that it’s terminating its ex-U.S. rights to Fampyra in order to focus on other priorities, which include expanding beyond MS.

Competition 124

Competition Sales Marketing Biopharma 124

PM360

MAY 21, 2024

sarah.caldwell@veeva.com SARAH CALDWELL General Manager Veeva Crossix Analytic Consumers’ TV viewing habits are changing, and streaming video continues to catapult in popularity, unearthing new opportunities for biopharma advertisers to reach patients in more targeted ways. According to Nielsen, streaming accounts for 38% of viewership hours.

Media 105

Media Healthcare Healthcare Marketing 105

Clarivate

DECEMBER 19, 2022

Either way, competition over employed providers among Medicare Advantage plans has only begun to heat up and UnitedHealth remains the plan to beat. Clarivate Associate Healthcare Research & Data Analysts Anubhav Sharma and Prashanth Jain contributed to this report. Medicare provider competition appeared first on Clarivate.

Competition 52

Competition Retail Insurance Marketing 52

PM360

SEPTEMBER 28, 2022

Now, as the President of Accord BioPharma , the U.S. PM360: From your time at Roche when you were dealing with biosimilars as potential competition to now leading the launch of biosimilars at Accord and Intas, how have you seen the marketplace for biosimilars evolve over that time? Look, competition is healthy.

Competition 98

Competition Marketing Manufacturing Biopharma 98

Clarivate

OCTOBER 25, 2021

OFF-X is already integrated with several Cortellis products, including Cortellis Drug Discovery Intelligence and Cortellis Competitive Intelligence. As a next step in this journey, Bioinfogate will be fully integrated into the Clarivate product portfolio and renamed.

Safety 110

Safety Biopharma Competition Management 110

Impetus Digital

MARCH 15, 2024

Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. This competitive intensity tends to focus on smaller patient populations with multiple treatment options (1,2). However, with rapid growth comes growing pains.

Recruitment 78

Recruitment Healthcare Provider Patients Healthcare 78

European Pharmaceutical Review

NOVEMBER 16, 2023

billion by 2032, according to Towards Healthcare. On the other hand, the author explained that these challenges are anticipated to be addressed through advances in technology, industry effort on implementation of standardisation and increased competition in the market. Could centrifugal bioreactor accelerate cell-therapy manufacturing?

Marketing 97

Marketing Manufacturing Biopharma Competition 97

Clarivate

JULY 31, 2023

Following the acquisition of Dialog Solutions as part of the ProQuest M&A in December 2021, Dialog Solutions products and services will be folded into the Clarivate portfolio of offerings for Life Sciences & Healthcare. To learn more about the Dialog platform, visit: here.

Healthcare 52

Healthcare Healthcare Safety Competition 52

PM360

MAY 10, 2024

May 9, 2024 /PRNewswire/ — VUE Health, a Boston-based healthcare advertising agency, has hired Zara Baker as Chief Digital Innovation Officer. Before that, she was the head of omnichannel strategy at Ionis Pharma and held senior digital roles at various healthcare and biopharma companies. SOURCE VUE Health

Healthcare 52

Healthcare Healthcare Biopharma Engineering 52

Veeva

DECEMBER 9, 2024

Embracing a mindset shift to pave the way for effective engagement models In an incredibly competitive market, field teams now must work harder than ever to stand out. Every interaction field teams have with healthcare professionals needs to add value and provide customers with the right material to inform key decisions.

Biopharma 52

Biopharma Healthcare Healthcare Marketing 52

PM360

NOVEMBER 27, 2023

I recently sat down with Erica Taylor, PhD, Vice President and Chief Marketing Officer at Genentech, to talk about the future of biopharma marketing and creating more meaningful content. Pooja Ojala: How do you approach marketing to adapt to today’s healthcare landscape?

Marketing 105

Marketing Customer Relationship Management Relationship management Education 105

MedCity News

JUNE 16, 2023

Regardless of the reasons, investors, pharma, and research organizations are recognizing that advanced digital health tools will be a significant competitive advantage and generate meaningful return on investment (ROI) in an industry that is becoming more personalized and specialized.

Pharma 123

Pharma Food and Drug Administration Recruitment Patients 123

Clarivate

JULY 5, 2023

The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. By end of year, as many as ten adalimumab biosimilars could be on the U.S. from 91% in 2023 to 36% by 2031.

Marketing 97

Marketing Physicians Manufacturing Competition 97

Clarivate

OCTOBER 17, 2024

Companies need to carefully assess the value of the assets being acquired or licensed, considering factors such as the stage of development, market potential, the competitive landscape and intellectual property protection.

Pharma 59

Pharma Competition Marketing Healthcare 59

Clarivate

DECEMBER 6, 2022

In a fiercely competitive U.S. healthcare provision landscape, integrated delivery networks, or IDNs, are differentiating their offerings by adding outpatient treatment centers, pursuing National Cancer Institute designations and investing in value-based care. Christopher Silva, Senior Healthcare Research Analyst.

Networking 52

Networking Healthcare Healthcare Competition 52

PM360

APRIL 22, 2024

In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience.

Education 59

Education Physicians Healthcare Healthcare 59

PM360

NOVEMBER 12, 2023

While the global biopharma industry retains its huge dependence on the U.S. This should, at least in theory, make them an appealing target for biopharma companies looking to expand beyond the hugely competitive markets of the U.S., market, emerging markets present great opportunities for biotech and pharmaceutical companies.

Marketing 59

Marketing Biopharma Government Pharma 59

Clarivate

MAY 31, 2023

According to figures from the Healthcare Research & Data Analytics team at Clarivate, the top three best-selling products for Pfizer, AbbVie, Merck/MSD and Bristol Myers Squibb contributed more than half their revenue in 2022, ranging from 53.3% of AbbVie’s $51.8 billion in revenue to a whopping 67.2% for Bristol Myers Squibb’s $44.7

Pharma 52

Pharma Biopharma Medicine Healthcare 52

European Pharmaceutical Review

DECEMBER 21, 2022

The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The lengthy validation of defossilised organic chemicals and plastics for the healthcare sector will take several years. The path to real zero.

Manufacturing 97

Manufacturing Pharmaceutical Healthcare Healthcare 97

Clarivate

MAY 8, 2024

Doubling down on strategic therapeutic areas Pharma once again finds itself having to narrow its sights on partnerships that deliver the next blockbuster and enable differentiation from the competition—all while navigating increasing regulatory scrutiny and shifting patient and payer expectations.

Pharma 59

Pharma Biopharma Prospecting Competition 59

European Pharmaceutical Review

DECEMBER 26, 2023

1 As revolutionary upstream and downstream technologies become a reality, biopharma companies will need to determine how best to integrate them into their current systems. 2 Capabilities in suspension cell lines and proprietary cell lines are becoming increasingly important to competitiveness within the gene therapy industry.

Manufacturing 98

Manufacturing Safety Patients Competition 98

European Pharmaceutical Review

DECEMBER 19, 2022

She has experience on issues arising during the lifecycle of medicinal products, including optimisation of IP regulatory rights, advertising, product liability, competition and market access issues. Chris was named a ‘Rising Star’ in the 2022 Legal 500 Rankings for Life Sciences and Healthcare. References/Endnotes. Lausuntopalvelu.fi.

Medicine 52

Medicine Biopharma Safety Food 52

Clarivate

OCTOBER 25, 2023

exclusions exist for orphan drug designation and biosimilar competition ). However, the ultimate impact of this program should have far-reaching effects for pharmaceutical companies and the broader healthcare system that bear monitoring as the IRA’s multi-year implementation schedule unfolds.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

MAY 24, 2023

In recent years, FDA has increasingly shown an openness to surrogate endpoints as the basis for approval of a therapy,” said Bethany Kiernan, Director of Healthcare Research Analytics for Infectious, Niche and Rare Diseases at Clarivate.

Patients 52

Patients Food and Drug Administration Biopharma FDA 52

The Marketing Advantage

SEPTEMBER 7, 2021

September 8, 2021 Over the years, the healthcare industry has progressively grown more and more complex, from the increasing influence of managed care companies to intensifying governmental regulations to new data sources. In parallel with this growing industry-wide complexity has been the call to further simplify sales compensation plans.

Sales 52

Sales Biopharma Marketing Management 52

Veeva

APRIL 28, 2024

As the pharmaceutical landscape grows more dynamic and competitive, life sciences companies are increasingly expected to develop more innovative brand launches, whilst juggling more complexity in marketing and interactions with healthcare professionals (HCPs).

Management 52

Management Marketing Distribution Biopharma 52

Clarivate

MARCH 12, 2024

For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.

Government 52

Government Marketing Physicians Biopharma 52

Quantified

JANUARY 3, 2023

You are going to see a dramatic change in leadership’s urgency to leverage AI This new creative AI era will fuel massive advances in personalized customer service, drive new business models, improve real-time modeling ( Southwest Airlines ) and pave the way for breakthroughs in healthcare and biopharma from Google ‘s DeepMind.

Biopharma 40

Biopharma Media Competition Training 40

Clarivate

SEPTEMBER 26, 2023

In therapeutic areas where there is competition for trial participants (e.g. If trial sponsors can access this data in a trusted and layered way, RWD will save dollars and lives, a win-win for all stakeholders in the healthcare ecosystem. oncology), trial productivity is essential.

Food and Drug Administration 59

Food and Drug Administration Patients Electronics Healthcare 59

European Pharmaceutical Review

OCTOBER 8, 2024

The event is a key platform for global supply chain connections, offering unmatched opportunities to form partnerships, secure contracts, and stay competitive. However, the venture capital branches of leading pharmaceutical firms are proving to be innovation engines, vital in fostering advances and addressing key healthcare issues.

Pharma 52

Pharma Manufacturing Pharmaceutical Management 52

Clarivate

OCTOBER 8, 2021

CVS Caremark manages pharmacy benefits for Molina Healthcare, Centene and Aetna, which hold a Medicaid contract in states that are transitioning to a single PBM. If more states move to a single PBM model, there could be rising competition to win a state contract that guarantees significant membership for a long period of time.

Government 52

Government Management Insurance Marketing 52

Clarivate

OCTOBER 7, 2021

As part of our Drugs to Watch series, which reviews therapies expected to have significant impact on healthcare markets, Clarivate oncology experts sifted through the more than 2,800 abstracts that were accepted for presentation at the ESMO 2021 Virtual Conference and selected their top picks.

Patients 91

Patients Safety Marketing Physicians 91

Pharmaceutical Technology

JUNE 15, 2023

Learn about how AI is helping companies right now, what to know about its benefits and challenges, and what’s needed to implement AI in biopharma research. AI and its healthcare applications will continue to evolve, but you can already realize many potential benefits. How is AI used in the pharmaceutical industry?

Pharma 52

Pharma Management Networking Manufacturing 52

PM360

SEPTEMBER 30, 2024

This article outlines how developers can utilize sustainability initiatives to boost revenue, reduce costs, and advance innovation, ensuring a strategic, long-term, and more sustainable position in today’s competitive landscape.

Manufacturing 52

Manufacturing Pharma Pharmaceutical Competition 52

Clarivate

DECEMBER 1, 2021

As part of our Drugs to Watch series, which reviews therapies expected to have significant impact on healthcare markets, Clarivate experts have selected their top picks from the AHA21 Scientific Sessions. In the following article, we present our analysis of five featured abstracts and our key takeaways for healthcare executives.

Patients 52

Patients Safety Management Marketing 52